Related Experiment Videos
Is it a medical error if we do not screen cirrhotic patients for minimal hepatic encephalopathy?
J C Quero Guillén1, M Groeneweg, M Jiménez Sáenz
1Department of Gastroenterology, University Hospital Virgen Macarena, Avda. Dr. Fedriani, 3, 41071 Sevilla, Spain. queroguillen@yahoo.es
Abstract:
Minimal hepatic encephalopathy (MHE) refers to subtle neurocognitive and neurophysiological defects in patients with liver cirrhosis without clinical signs of hepatic encephalopathy. Using appropriate diagnostic methods the prevalence of MHE is approximately 25-30%. MHE has clinical significance as it results in a diminished daily functioning, precedes overt hepatic encephalopathy and is associated with a poor prognosis. Treatment with non-absorbable disaccharides can reverse the neurocognitive and neurophysiological defects found in MHE. The failure to diagnose MHE in apparently normal cirrhotic patients could, therefore, be considered a medical error. However, whether treatment also improves patients' quality of life and prognosis remains to be determined.
Insights
Minimal hepatic encephalopathy (MHE) affects 25-30% of liver cirrhosis patients, causing subtle neurocognitive deficits. Treatment with non-absorbable disaccharides can reverse these MHE defects, but impact on quality of life and prognosis requires further study.
Area of Science:
- Hepatology
- Neurology
- Gastroenterology
Background:
- Minimal hepatic encephalopathy (MHE) presents as subtle neurocognitive and neurophysiological impairments in liver cirrhosis patients without overt symptoms.
- MHE affects an estimated 25-30% of individuals with liver cirrhosis.
- This condition significantly impacts daily functioning, precedes overt hepatic encephalopathy, and is linked to a poorer prognosis.
Purpose of the Study:
- To highlight the clinical significance of diagnosing MHE in liver cirrhosis patients.
- To discuss the potential for non-absorbable disaccharides in treating MHE.
- To identify the need for further research on MHE treatment's effect on quality of life and prognosis.
Main Methods:
- Diagnostic methods for identifying subtle neurocognitive and neurophysiological defects were employed.
- Prevalence rates of MHE in liver cirrhosis patients were assessed.
- The efficacy of non-absorbable disaccharides in reversing MHE-related defects was evaluated.
Main Results:
- The prevalence of MHE in liver cirrhosis patients is approximately 25-30%.
- Non-absorbable disaccharides demonstrated the ability to reverse neurocognitive and neurophysiological defects associated with MHE.
- Failure to diagnose MHE in cirrhotic patients may be considered a medical oversight.
Conclusions:
- MHE is a prevalent condition in liver cirrhosis with significant clinical implications.
- Current treatments can effectively reverse MHE-related neurocognitive and neurophysiological deficits.
- Further investigation is crucial to determine if MHE treatment improves patient quality of life and long-term prognosis.